Table 1.

Characteristics of randomized controlled studies included in this meta-analysis

Ref.	Sample size (I/C)	Achilles tendon lesion	Location	Control	Follow-up	PRP injection frequency/interval/dose (mL)
de Vos et al[42], 2010	27/27	C-AT (> 2 mo)	Netherlands	Saline	6, 12, 24 wk	Once/-/4
de Jonge et al[41], 2011	27/27	C-AT (> 2 mo)	Netherlands	Saline	6, 12, 24, 48 wk	Once/-/4
Kearney et al[50], 2013	9/10	C-AT (> 8 mo)	United Kingdom	Blank	6 wk, 3 mo, 6 mo	Once/-/3 to 5
Krogh et al[22], 2016	12/12	C-AT (mean 33 mo)	Denmark	Saline	3, 6, 12 mo	Once/-/6
Boesen et al[21], 2017	19/19	C-AT (> 3 mo)	Denmark	Saline	6, 12, 24 wk	4 times/2-wk/4
van der Vlist et al[53], 2020	39/41	C-AT (> 6 mo)	Netherlands	Saline	2, 6, 12, 24 wk	Once/-/NR
Thermann et al[51], 2020	17/19	C-AT (> 6 mo)	Italy	Blank	6 wk, 3, 6, 12 mo	Once/-/NR
Kearney et al[52], 2021	121/119	C-AT (> 3 mo)	United Kingdom	Blank	2 wk, 3, 6 mo	Once/-/3
Schepull et al[28], 2011	15/14	A-ATR (< 3 d)	Sweden	Blank	6, 12 mo	Once/-/10/4
De Carli et al[49], 2015	15/15	A-ATR	Italy	Blank	1, 3, 6, 24 mo	2 times/2-wk/4
Zou et al[27], 2016	16 /20	A-ATR (< 3 wk)	China	Placebo	3 wk, 3, 6, 12, 24 mo	Once/-/NR
Keene et al[33], 2019	107/109	A-ATR (< 12 d)	United Kingdom	Placebo	4, 7, 13, 24 wk	Once/-/4
Boesen et al[34], 2020	19/19	A-ATR (< 3 d)	Denmark	Saline	8 wk, 3, 6, 12 mo	Once/-/4

PRP: Platelet-Rich Plasma; AT: Achilles tendinopathy; ATR: Achilles tendon rupture.